Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,413.83 -11.02 -0.07%
S&P 500 1,866.12 3.81 0.20%
NASDAQ 4,096.72 10.50 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Apricus Biosciences Announces Third Quarter 2012 Financial Results Conference Call



Apricus Biosciences Announces Third Quarter 2012 Financial Results Conference
Call

Conference Call/Webcast to be Held Friday, November 9, 2012 at 10:30 a.m. ET

SAN DIEGO, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com)
announced today that it will hold a conference call to discuss its third
quarter 2012 financial results and recent corporate highlights on Friday,
November 9, 2012 at 10:30 a.m. ET. The Company expects to file its Form 10-Q
for the quarter ended September 30, 2012 by the close of business on Thursday,
November 8, 2012.

The call can be accessed in the U.S. by dialing 877-407-8031 and outside of
the U.S. by dialing 201-689-8031 and asking the conference operator for the
Apricus Bio Conference Call. The teleconference replay will be available for
one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by
dialing 201-612-7415. Replay passcode 403400 is required for playback. The
conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=170122. The webcast replay
will be available for three months.

About Apricus Biosciences, Inc.

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patients populations across
numerous, high-demand therapeutic classes. The Company has four approved
products and has developed a strong pipeline of multiple late-stage product
candidates. With commercial operations in both the U.S. and Europe (France),
Apricus Bio generates revenues and growth from sales of its commercial
products and by out-licensing, in certain territories, its pipeline products
and NexACT® technology.

Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Takeda, Abbott Laboratories, Sandoz, Warner Chilcott and Bracco, and
co-promotes multiple products in France.

Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI.

For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its ability to further develop its
products and product candidates, to have its products and product candidates
receive patent protection and be approved by relevant regulatory authorities,
to successfully commercialize such products as Tolnaftate-D^™, Totect^®,
Granisol^®, Aquoral^™ and NitroMist^™ and Vitaros^® for erectile dysfunction
and NexACT^® product candidates and drug delivery technology and to achieve
its development, commercialization and financial goals. Readers are cautioned
not to place undue reliance on these forward-looking statements as actual
results could differ materially from the forward-looking statements contained
herein. Readers are urged to read the risk factors set forth in the Company's
most recent annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports are
available from the SEC's website or without charge from the Company.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Apricus logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement